Free tool
FAERS Monitor: Intelence
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022187 or its brand name (Intelence, Etravirine). Reports on generic versions are filed under their own applications.
Reports
4,438
Serious
3,903
88% of reports
Hospitalization
1,291
Death reported
475
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain286
- drug interaction282
- drug resistance266
- anxiety247
- emotional distress243
- virologic failure237
- anhedonia219
- death208
- treatment failure203
- chronic kidney disease192
- lipodystrophy acquired175
- foetal exposure during pregnancy166
- renal failure165
- anaemia163
- drug ineffective160
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 59 |
| 2008 | 153 |
| 2009 | 255 |
| 2010 | 257 |
| 2011 | 196 |
| 2012 | 278 |
| 2013 | 265 |
| 2014 | 257 |
| 2015 | 375 |
| 2016 | 343 |
| 2017 | 267 |
| 2018 | 250 |
| 2019 | 317 |
| 2020 | 369 |
| 2021 | 222 |
| 2022 | 231 |
| 2023 | 158 |
| 2024 | 93 |
| 2025 | 45 |
| 2026 | 48 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,721 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lipodystrophy acquiredSignal | 175 | 425.7 | 365.7 | 67,653 |
| virologic failureSignal | 237 | 218.4 | 192.4 | 48,844 |
| drug resistanceSignal | 266 | 49.6 | 44.1 | 12,498 |
| anhedoniaSignal | 219 | 39.8 | 35.0 | 8,190 |
| chronic kidney diseaseSignal | 192 | 12.0 | 10.5 | 1,928 |
| treatment failureSignal | 203 | 11.6 | 10.2 | 1,966 |
| foetal exposure during pregnancySignal | 166 | 9.7 | 8.4 | 1,288 |
| emotional distressSignal | 243 | 9.5 | 8.4 | 1,854 |
| drug interactionSignal | 282 | 8.4 | 7.5 | 1,852 |
| renal failureSignal | 165 | 5.9 | 5.1 | 669 |
| anxietySignal | 247 | 4.1 | 3.6 | 587 |
| anaemiaSignal | 163 | 4.1 | 3.5 | 375 |
| painSignal | 286 | 2.2 | 2.0 | 193 |
| death | 208 | 1.1 | 1.0 | 4 |
| drug ineffective | 160 | 0.6 | 0.5 | 53 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.